Savara Announces New Employment Inducement Grant
Savara Inc. (SVRA) has granted inducement awards to five new employees, as announced by the company's Compensation Committee on February 12, 2025. The awards include:
- Stock options to purchase 97,500 shares with an exercise price of $2.75 per share, vesting quarterly over four years (1/16th per quarter)
- Restricted stock units (RSUs) covering 82,500 shares, vesting fully after two years
These equity awards were granted under Savara's 2021 Inducement Equity Incentive Plan, complying with NASDAQ Listing Rule 5635(c)(4). The stock options have a 10-year term, and both options and RSUs are subject to continued employment through their respective vesting dates.
Savara Inc. (SVRA) ha concesso premi di indennizzo a cinque nuovi dipendenti, come annunciato dal Comitato per la Compensazione dell'azienda il 12 febbraio 2025. I premi includono:
- Opzioni su azioni per l'acquisto di 97.500 azioni a un prezzo di esercizio di $2,75 per azione, con maturazione trimestrale su un periodo di quattro anni (1/16 ogni trimestre)
- Unità di azioni vincolate (RSU) per 82.500 azioni, che maturano completamente dopo due anni
Questi premi azionari sono stati concessi nell'ambito del Piano di Incentivazione Azionaria per Indennizzo del 2021 di Savara, in conformità con la Regola di Quotazione NASDAQ 5635(c)(4). Le opzioni su azioni hanno una durata di 10 anni e sia le opzioni che le RSU sono soggette a un'occupazione continuativa fino alle rispettive date di maturazione.
Savara Inc. (SVRA) ha otorgado premios de incentivo a cinco nuevos empleados, como anunció el Comité de Compensación de la empresa el 12 de febrero de 2025. Los premios incluyen:
- Opciones sobre acciones para comprar 97,500 acciones a un precio de ejercicio de $2.75 por acción, con un vesting trimestral durante cuatro años (1/16 por trimestre)
- Unidades de acciones restringidas (RSUs) que cubren 82,500 acciones, con vesting completo después de dos años
Estos premios de capital se otorgaron bajo el Plan de Incentivo de Capital por Inducción 2021 de Savara, cumpliendo con la Regla de Cotización NASDAQ 5635(c)(4). Las opciones sobre acciones tienen un plazo de 10 años, y tanto las opciones como las RSUs están sujetas a empleo continuo hasta sus respectivas fechas de vesting.
사바라 Inc. (SVRA)는 2025년 2월 12일 회사 보상 위원회에 의해 발표된 바와 같이 다섯 명의 신입 직원에게 유인 보상을 지급했습니다. 보상 내용은 다음과 같습니다:
- $2.75의 행사 가격으로 97,500주를 구매할 수 있는 주식 옵션, 4년 동안 분기별로 1/16씩 귀속됨
- 82,500주에 대한 제한된 주식 단위(RSU), 2년 후 전량 귀속
이 자산 보상은 사바라의 2021년 유인 자본 인센티브 계획에 따라 NASDAQ 상장 규칙 5635(c)(4)에 부합하여 지급되었습니다. 주식 옵션은 10년의 유효 기간을 가지며, 옵션과 RSU 모두 각각의 귀속 날짜까지 계속 고용되어야 합니다.
Savara Inc. (SVRA) a accordé des primes d'incitation à cinq nouveaux employés, comme l'a annoncé le Comité de rémunération de l'entreprise le 12 février 2025. Les primes comprennent :
- Des options d'achat d'actions pour acquérir 97 500 actions à un prix d'exercice de 2,75 $ par action, avec un droit d'acquisition trimestriel sur quatre ans (1/16 par trimestre)
- Des unités d'actions restreintes (RSU) couvrant 82 500 actions, acquises entièrement après deux ans
Ces primes en actions ont été accordées dans le cadre du Plan d'incitation en capital de 2021 de Savara, conformément à la règle de cotation NASDAQ 5635(c)(4). Les options d'achat d'actions ont une durée de 10 ans, et les options ainsi que les RSU sont soumises à un emploi continu jusqu'à leurs dates d'acquisition respectives.
Savara Inc. (SVRA) hat fünf neuen Mitarbeitern Anreizprämien gewährt, wie vom Vergütungsausschuss des Unternehmens am 12. Februar 2025 angekündigt. Die Prämien umfassen:
- Aktienoptionen zum Kauf von 97.500 Aktien zu einem Ausübungspreis von 2,75 $ pro Aktie, die vierteljährlich über vier Jahre (1/16 pro Quartal) fällig werden
- Eingeschränkte Aktieneinheiten (RSUs) für 82.500 Aktien, die nach zwei Jahren vollständig fällig werden
Diese Eigenkapitalprämien wurden im Rahmen des Anreizkapitalplans 2021 von Savara gewährt und entsprechen der NASDAQ-Listing-Regel 5635(c)(4). Die Aktienoptionen haben eine Laufzeit von 10 Jahren und sowohl Optionen als auch RSUs sind an eine fortdauernde Beschäftigung bis zu ihren jeweiligen Fälligkeitsdaten gebunden.
- None.
- None.
On February 12, 2025, the Compensation Committee of Savara's Board of Directors granted the inducement awards to five new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of 97,500 shares of the Company’s common stock and restricted stock units (RSUs) covering an aggregate of 82,500 shares of the Company’s common stock. These equity awards were granted under the Savara Inc. 2021 Inducement Equity Incentive Plan pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules as an inducement material to the employees’ acceptance of employment with the Company.
The options have an exercise price of
About Savara
Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, MOLBREEVI*, is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com, and LinkedIn.
*MOLBREEVI is the FDA and EMA conditionally accepted trade name for molgramostim inhalation solution.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250214881065/en/
Media and Investor Relations Contact
Savara Inc.
Temre Johnson, Executive Director, Corporate Affairs
ir@savarapharma.com
Source: Savara Inc.
FAQ
How many shares are included in SVRA's February 2025 inducement awards?
What is the exercise price for SVRA's February 2025 inducement stock options?
What is the vesting schedule for SVRA's February 2025 inducement RSUs?
How long is the vesting period for SVRA's February 2025 stock options?
